Trends to Watch in 2016 – Part 2

We started the year off in January by reviewing three of the major trends of 2015 and reflecting on where we saw events headed in 2016. In part 2 of this post, which follows yesterday’s celebration of Rare Disease… Read »

Orphan Drug Franchises Best Left to Mature Alone

Commercial success in the rare disease field depends on a highly patient-centric approach that connects effectively with rare disease patient communities at a senior management level and focuses on access and interactions with thought leaders and physicians, rather than on… Read »

Increasing Role for Biomarkers in R&D, Clinical Medicine, and Pharma Marketing

Bionest team member Rachel Laing recently contributed to a feature in the January issue of PharmaVoice on the growing role and prominence of biomarker strategies in drug development and commercialization. In addition to helping to better identify those patients who will… Read »

Happy New Year! Here Are Three Key Areas to Watch in 2016

First of all, we at Bionest want to wish you a very happy, healthy, and prosperous new year.  And we look forward to speaking to many of you in person during JP Morgan week in San Francisco!   Another year… Read »

Visit Us at the JP Morgan Healthcare Conference – Jan 11-14 in San Francisco!

We are looking forward to attending the JP Morgan Healthcare Conference again January 11-14, 2016, in San Francisco.   Three of Bionest’s leaders, Alain J. Gilbert, Olivier Lesueur, and Bob Easton, will be available to meet one-on-one for 30 minutes… Read »

ASH News on CAR-T Therapies Reinforces Previous Enthusiasm for the Approach… But Challenges Remain

CAR-T therapies involve removing T cells from individual patients and engineering them to recognize and destroy that patient’s cancer. Early clinical results over the last few years raised considerable interest in this cell-based immunotherapeutic approach, and now that several… Read »

BIO Europe 2015 Conference – Reflections

Bionest attended BIO Europe in Munich last month and witnessed firsthand the flurry of deal making activity.  In many ways 2015 has been a landmark year for deal making.  Companies big and small have made headlines, striking deals across every… Read »

Promise of Immunotherapy Featured on Today Show

The recent news of Jimmy Carter’s excellent response to cancer immunotherapy — he reported earlier this week that his brain cancer appears to be gone following treatment with Keytruda — was highlighted this morning on the  Today Show.  The field… Read »

Data Is Key to Forming Immunotherapy Partnerships

We were pleased to participate in a “State of the Industry” panel on immuno-oncology at the 2015 BIO Investor Forum in October. The lively discussion included other participants from across the industry and investing world, including the licensing office of… Read »

Welcome to the Bionest Blog!

The world health environment is changing quickly. Advances in science and technology, as well as political and economic trends, are having a major impact on the development, commercialization, and delivery of effective health care around the world. We work closely… Read »

1 4 5 6